Infographic: COPD Market To Reach $23.7Bn By 2022
The market for devices to treat chronic obstructive pulmonary disease (COPD) is set to grow by 5.0% annually in the next three years, with the US market expanding by 5.7% per year, according to the Meddevicetracker Dashboard.
You may also be interested in...
Approval for Boston Scientific’s TheraSphere offers further access to the therapy that, until now, has only been available under a humanitarian device exemption.
The UK-based company is seeking to raise a further $100m in 2021 following the recent US clearance of its first product, a daytime-use neurostimulation device for snoring and mild obstructive sleep apnea.
The deal combines two of the largest providers of sterilization and infection-prevention products to create a $4bn-plus-revenue business.